Legal Representation
Attorney
Rosemary S. Tarlton
USPTO Deadlines
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 16, 2005 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 16, 2005 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Apr 5, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 5, 2005 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Apr 5, 2005 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Sep 30, 2004 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Sep 21, 2004 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 21, 2004 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Apr 9, 2004 | CFIT | O | CASE FILE IN TICRS | Loading... |
| Mar 31, 2004 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 31, 2004 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Mar 31, 2004 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 6, 2003 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 6, 2003 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 6, 2003 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 14, 2003 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 28, 2003 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 28, 2003 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 8, 2002 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 16, 2002 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 26, 2002 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| May 7, 2002 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 14, 2002 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 31, 2001 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Aug 27, 2001 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 005
Housemark for pharmaceuticals and pharmaceutical components; pharmaceuticals, namely, treatment for central nervous system disorders, cancer and other serious and life-threatening diseases
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
TITAN
Classification
International Classes
005